These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10777343)

  • 1. [HIV therapy: toxic liver injuries caused by protease inhibitors?].
    Kunde K
    Dtsch Med Wochenschr; 2000 Mar; 125(12):A12-3. PubMed ID: 10777343
    [No Abstract]   [Full Text] [Related]  

  • 2. Disorders of iron metabolism associated with protease inhibitor therapy.
    McNabb JC; Cappa JA; Ross JW
    Clin Infect Dis; 2001 Aug; 33(3):413-4. PubMed ID: 11438916
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV and the liver.
    Rockstroh J
    J HIV Ther; 2009 Mar; 14(1):2-3. PubMed ID: 19731557
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic interventions for HIV infection and chronic viral hepatitis.
    Cooper CL
    Clin Infect Dis; 2005 Jul; 41 Suppl 1():S69-72. PubMed ID: 16265617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?
    Bani-Sadr F; Goderel I; Morand P; Payan C; Lunel F; Pol S; Perronne C; Carrat F; Cacoub P
    AIDS; 2007 Jul; 21(12):1645-8. PubMed ID: 17630563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients.
    Torti C; Lapadula G; Uccelli MC; Quiros-Roldan E; Regazzi M; Ladisa N; Micheli V; Orani A; Patroni A; Caputo SL; Tirelli V; Di Giambenedetto S; Cologni G; Costarelli S; Gargiulo F; Manca N; Carosi G;
    Int J Antimicrob Agents; 2007 Feb; 29(2):185-90. PubMed ID: 17011754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Cicconi et al. 'Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?'.
    Núñez M
    AIDS; 2007 Jul; 21(12):1660. PubMed ID: 17630570
    [No Abstract]   [Full Text] [Related]  

  • 8. Summary of BHIVA guidelines for HIV and hepatitis B or C co-infection.
    Brook MG
    J HIV Ther; 2003 Nov; 8(4):85-8. PubMed ID: 14671505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():60-1. PubMed ID: 19031566
    [No Abstract]   [Full Text] [Related]  

  • 10. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
    Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
    HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
    Cicconi P; Cozzi-Lepri A; Phillips A; Puoti M; Antonucci G; Manconi PE; Tositti G; Colangeli V; Lichtner M; Monforte Ad;
    AIDS; 2007 Mar; 21(5):599-606. PubMed ID: 17314522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis viruses and human immunodeficiency virus co-infection: pathogenesis and treatment.
    Vallet-Pichard A; Pol S
    J Hepatol; 2004 Jul; 41(1):156-66. PubMed ID: 15246224
    [No Abstract]   [Full Text] [Related]  

  • 13. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.
    Alberti A; Clumeck N; Collins S; Gerlich W; Lundgren J; Palù G; Reiss P; Thiebaut R; Weiland O; Yazdanpanah Y; Zeuzem S;
    J Hepatol; 2005 May; 42(5):615-24. PubMed ID: 15916745
    [No Abstract]   [Full Text] [Related]  

  • 14. Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis.
    Martín-Carbonero L; Barreiro P; Jiménez-Galán G; García-Berriguete R; Núñez M; Ríos P; González-Lahoz J; Soriano V
    J Viral Hepat; 2007 Jun; 14(6):392-5. PubMed ID: 17501759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis.
    Soriano V; Barreiro P; Martín-Carbonero L; Castellares C; Ruiz-Sancho A; Labarga P; Ramos B; Gonzalez-Lahoz J
    J Infect Dis; 2007 Apr; 195(8):1181-3. PubMed ID: 17357055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic safety and HAART.
    McGovern B
    J Int Assoc Physicians AIDS Care (Chic); 2004 Nov; 3 Suppl 2():S24-40. PubMed ID: 15673131
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatitis B or hepatitis C and human immunodeficiency virus infection.
    Thimme R; Spangenberg HC; Blum HE
    J Hepatol; 2005; 42 Suppl(1):S37-44. PubMed ID: 15777571
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection.
    Asmuth DM; Busch MP; Laycock ME; Mohr BA; Kalish LA; van der Horst CM;
    Antiviral Res; 2004 Aug; 63(2):123-31. PubMed ID: 15302141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Issues in diagnostic testing and monitoring in HIV/viral hepatitis co-infection.
    Dervisevic S; Pillay D
    J HIV Ther; 2003 Nov; 8(4):89-95. PubMed ID: 14671506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa.
    Cooper CL; Mills E; Wabwire BO; Ford N; Olupot-Olupot P
    Int J Infect Dis; 2009 May; 13(3):302-6. PubMed ID: 19004656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.